In immunotherapy, particularly immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 and anti-CTLA-4 therapies [4], studies have shown that maintaining VD levels within the normal range during anti-PD-1 immunotherapy is necessary to ensure treatment efficacy in patients with advanced melanoma [37,84]. The gene discussed is CTLA4; the disease is melanoma.